PF-07104091 monotherapy dose escalation

Phase 2

PFIZER (PFE)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

days

PFEPhase 2$142.7B

PF-07104091 monotherapy dose escalation Phase 2 Results Expected

PF-07104091 monotherapy dose escalation• Small Cell Lung Cancer154

Mar 30Estimated

CT.gov

00%

Competitive Landscape

4 competitors in Small Cell Lung Cancer

Drug Information

Target Indication

Small Cell Lung Cancer

Clinical Trial

NCT04553133

Last updated: 3/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Healthcare•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Cyclosporine APhase 3

Renal Transplantation

Insulin LisproPhase 3

Diabetes Mellitus

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

MeropenemPhase 3

Complicated Intra-abdominal Infections

View full pipeline